Role of the Histone Deacetylase Inhibitor Givinostat (ITF2357) in Treatment of CRLF2 Rearranged Acute Lymphoblastic Leukemia

被引：0
|
作者：
Savino, Angela Maria [1 ]
Sarno, Jolanda [1 ]
Trentin, Luca [2 ]
Vieri, Margherita [1 ]
Fazio, Grazia [1 ]
Bardini, Michela [1 ]
Bugarin, Cristina [1 ]
Fossati, Gianluca [3 ]
Davis, Kara L. [4 ]
Gaipa, Giuseppe
Meyer, Lueder Hinrich [5 ]
Nolan, Garry P. [6 ]
Biondi, Andrea [7 ]
Kronnie, Geertruy Te [8 ]
Palmi, Chiara [1 ]
Cazzaniga, Giovanni [1 ]
机构：
[1] Univ Milano Bicocca, Dept Pediat, Ctr Ric Tettamanti, Fdn MBBM,San Gerardo Hosp, Monza, Italy
[2] Univ Padua, Dept Womens & Childrens Hlth 2, Padua, Italy
[3] Italfarmaco SpA, Preclin R&D Dept 3, Milan, Italy
[4] Stanford Univ, Pediat, Palo Alto, CA 94304 USA
[5] Univ Ulm, Med Ctr, Dept Pediat & Adolescent Med, D-89069 Ulm, Germany
[6] Stanford Univ, Sch Med, Baxter Lab Stem Cell Biol, Dept Microbiol & Immunol, Palo Alto, CA 94304 USA
[7] Univ Milano Bicocca, Clin Pediat, Ctr Ric Tettamanti, Osped San Gerardo,Fdn MBBM, Monza, MB, Italy
[8] Univ Padua, Dept Womens & Childrens Hlth, Padua, Italy
来源：
BLOOD | 2015年 / 126卷 / 23期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] ROLE OF THE HYSTONE DEACETYLASE INHIBITOR GIVINOSTAT (ITF2357) IN TREATMENT OF CRLF2 REARRANGED ACUTE LYMPHOBLASTIC LEUKEMIA
    Savino, A. M.
    Palmi, C.
    Fazio, G.
    Bardini, M.
    Rizzo, F.
    Cazzaniga, V.
    Bugarin, C.
    Fossati, G.
    Biondi, A.
    Cazzaniga, G.
    HAEMATOLOGICA, 2014, 99 : 5 - 6
  • [2] THE HISTONE DEACETYLASE INHIBITOR GIVINOSTAT (ITF2357) HAS A POTENT ANTI-TUMOR ACTIVITY AGAINST CRLF2 REARRANGED LEUKEMIA
    Savino, A. M.
    Sarno, J.
    Trentin, L.
    Vieri, M.
    Fazio, G.
    Bardini, M.
    Bugarin, C.
    Fossati, G.
    Davis, K.
    Gaipa, G.
    Meyer, L.
    Nolan, G.
    Biondi, A.
    te Kronnie, T.
    Palmi, C.
    Cazzaniga, G.
    HAEMATOLOGICA, 2016, 101 : 198 - 198
  • [3] The histone deacetylase inhibitor givinostat (ITF2357) exhibits potent anti-tumor activity against CRLF2-rearranged BCP-ALL
    A M Savino
    J Sarno
    L Trentin
    M Vieri
    G Fazio
    M Bardini
    C Bugarin
    G Fossati
    K L Davis
    G Gaipa
    S Izraeli
    L H Meyer
    G P Nolan
    A Biondi
    G Te Kronnie
    C Palmi
    G Cazzaniga
    Leukemia, 2017, 31 : 2365 - 2375
  • [4] The histone deacetylase inhibitor givinostat (ITF2357) exhibits potent anti-tumor activity against CRLF2-rearranged BCP-ALL
    Savino, A. M.
    Sarno, J.
    Trentin, L.
    Vieri, M.
    Fazio, G.
    Bardini, M.
    Bugarin, C.
    Fossati, G.
    Davis, K. L.
    Gaipa, G.
    Izraeli, S.
    Meyer, L. H.
    Nolan, G. P.
    Biondi, A.
    Kronnie, G. Te
    Palmi, C.
    Cazzaniga, G.
    LEUKEMIA, 2017, 31 (11) : 2365 - 2375
  • [5] Synergistic drug interactions of the histone deacetylase inhibitor givinostat (ITF2357) in CRLF2-rearranged pediatric B-cell precursor acute lymphoblastic leukemia identified by high-throughput drug screening
    Oikonomou, Athanasios
    Watrin, Titus
    Valsecchi, Luigia
    Scharov, Katerina
    Savino, Angela Maria
    Schliehe-Diecks, Julian
    Bardini, Michela
    Fazio, Grazia
    Bresolin, Silvia
    Biondi, Andrea
    Borkhardt, Arndt
    Bhatia, Sanil
    Cazzaniga, Giovanni
    Palmi, Chiara
    HELIYON, 2024, 10 (13)
  • [6] Effects of the Histone Deacetylase Inhibitor ITF2357 in Autoinflammatory Syndromes
    Evelien J Bodar
    Anna Simon
    Jos W M van der Meer
    Molecular Medicine, 2011, 17 : 363 - 368
  • [7] Effects of the Histone Deacetylase Inhibitor ITF2357 in Autoinflammatory Syndromes
    Bodar, Evelien J.
    Simon, Anna
    van der Meer, Jos W. M.
    MOLECULAR MEDICINE, 2011, 17 (5-6) : 363 - 368
  • [8] Chemosensitization and radiosensitization effects of glioblastoma cells by the histone deacetylase inhibitor, givinostat (ITF2357) in glioblastoma cell models
    Gravina, G. L.
    Leoni, F.
    Benedetti, E.
    Delle Monache, S.
    Mancini, A.
    Angelucci, A.
    Di Cesare, E.
    Cimini, A. M.
    Porro, G.
    Festuccia, C.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S211 - S211
  • [9] Histone deacetylase inhibitor ITF2357 (givinostat) reverts transformed phenotype and counteracts stemness in in vitro and in vivo models of human glioblastoma
    Francesco Marampon
    Flavio Leoni
    Andrea Mancini
    Ilaria Pietrantoni
    Silvia Codenotti
    Ferella Letizia
    Francesca Megiorni
    Giuliana Porro
    Elisabetta Galbiati
    Pietro Pozzi
    Paolo Mascagni
    Alfredo Budillon
    Roberto Maggio
    Vincenzo Tombolini
    Alessandro Fanzani
    Giovanni Luca Gravina
    Claudio Festuccia
    Journal of Cancer Research and Clinical Oncology, 2019, 145 : 393 - 409
  • [10] Potent cytotoxicity against multiple myeloma and acute myeloid leukemia cells by a new histone deacetylase inhibitor ITF2357
    Rambaldi, A
    Mici, C
    Cuppini, L
    Domenghini, M
    Borleri, GM
    Barbui, AM
    Leoni, F
    Mascagni, P
    Salvi, A
    Golay, J
    Introna, M
    BLOOD, 2005, 106 (11) : 939A - 939A
12345